News for Emergent BioSolutions Inc. (EBS)

Stocks in news: IndusInd Bank, Hindustan Zinc, IIFL Finance, BEL, NTPC and more

PR NewswireBANGALORE, India, March 10, 2025 Expected to enhance global innovator flexibility with biologics drug substance facility in BaltimoreBANGALORE,

**media[562046]**

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Total Revenue (Q4 2024): $195 million, down from the prior year.Adjusted EBITDA (Q4 2024): $21 million, an increase of $18 million year-over-year.Adjusted Gros

Mar 03, 2025 / 10:00PM GMTOperator Good day and thank you for standing by. Welcome to Merchant buyer Solutions Inc. fourth quarter 2024 earnings conference call

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ETCompany ParticipantsFrank Vargo - Assistant TreasurerJoseph...

The following slide deck was published by Emergent BioSolutions Inc.

Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in N

Revenue: $194.7 million for Q4 2024, missing the estimated $254.67 million, reflecting a 30% decline from the previous year.Net Loss: $31.3 million for Q4 2024

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.

Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA)

Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 GAITHERSBURG, Md., Feb. 18, 2025

**media[534991]**

Shares of Emergent BioSolutions Inc (EBS) surged 3.78% in mid-day trading on Jan 31. The stock reached an intraday high of $11.60, before settling at $11.53,

Shares of Emergent BioSolutions Inc (EBS) surged 3.40% in mid-day trading on Jan 24. The stock reached an intraday high of $11.98, before settling at $11.87,

Emergent BioSolutions (EBS) has entered into an agreement for the exclusive commercial rights in the U.S. and Canada for Hikma's opioid overdose product Kloxxado. Read more here.

mergent BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more details here.

**media[513868]**